Document is current
Any future updates will be listed below
-
Authors
Lukowiak, Tess M. https://orcid.org/0000-0002-5914-1823
Cahn, Brian
Samie, Faramarz
Leffell, David J.
Oro, Anthony
Kibbi, Nour
Kheterpal, Meenal
Babakoohi, Shahab
Khushalani, Nikhil I.
Stephenson, Alice
Ma, Melissa Sayaphupha
Shi, Victoria J.
Ahmed, Areeba
Koza, Eric
Haq, Misha
Yi, Michael D.
Nadir, Umer
Yoo, Simon
Brieva, Joaquin C.
Lucas, Jennifer
Haber, Roger
Alam, Murad
- License Information
-
More Information
Article History
Received: 22 May 2024
Revised: 22 May 2024
Accepted: 23 May 2024
First Online: 5 July 2024
Declarations
: Nikhil I. Khushalani reports consulting or advisory roles with AstraZeneca, Bristol Myers Squibb, Castle Biosciences, Immunocore, Incyte, Instil Bio, Iovance Biotherapeutics, Merck, Nektar, Novartis, Regeneron Pharmaceuticals, Inc., and Replimune; research funding with Bristol Myers Squibb, Celgene, GSK, HUYA Bioscience International, Merck, Modulation Therapeutics, Novartis, Regeneron Pharmaceuticals, Inc., and Replimune; stock and other ownership interests with Amarin Corporation, Asensus Surgical, and Bellicum Pharmaceuticals; travel/ accommodation expenses with Regeneron Pharmaceuticals, Inc. and Castle Biosciences; study steering committee and/or scientific advisory board with Bristol Myers Squibb, Nektar, Regeneron Pharmaceuticals, Inc., Replimune, and T-knife Therapeutics.
: The authors declare no competing interests.
